ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
43 announcements
Anlon Healthcare incorporated ANLON Healthcare Nigeria Limited, holding 90% stake. The subsidiary aims to expand pharmaceutical and healthcare operations across 16 West African countries.
Anlon Healthcare's AGM approved acquiring Apiqo Organics and Bizotic Lifescience stakes via share swap. The filing adds preferential issue pricing of ₹17.85 per share.
Anlon Healthcare responded to NSE/BSE surveillance queries stating no undisclosed information explains the price movement. The company attributes the move to market-driven factors.
Brickwork Ratings assigned BWR BBB/Stable to Anlon Healthcare's ₹23.60 Crore fund-based term loan. The rating reflects improved profitability and low leverage following the company's 2025 IPO.
Anlon Healthcare Limited held its 13th Annual General Meeting on September 05, 2025. Shareholders considered financial statements, director appointments, and a preferential issue of equity shares.
Anlon Healthcare issued a corrigendum to its 13th AGM Notice, revising details for proposed preferential share allotments. The AGM is scheduled for September 5, 2026.
Anlon Healthcare Limited issued a notice for its 13th Annual General Meeting on September 5, 2026. The agenda includes financial statements and director appointments.
Anlon Healthcare Limited has filed its Annual Report for the financial year 2025-2026. This submission complies with Regulation 34 of the SEBI Listing Regulations.
Anlon Healthcare's 13th AGM, scheduled for September 5, 2026, proposes key business items, including the acquisition of Apiqo Organics and share capital enhancement.
Anlon Healthcare Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026, as required under SEBI regulations.
Anlon Healthcare will acquire significant stakes in Apiqo Organics (44.94%) and Bizotic Lifescience (47.41%) for a total consideration of approximately ₹153.30 Crore. Acquisitions involve a share swap via preferential issue.
Anlon Healthcare Q1 FY27 results show strong top-line growth following the acquisition of Remember India Health Links, though EBITDA margins faced temporary pressure from surging raw material costs and consolidation expenses.
Anlon Healthcare executed agreements to acquire stakes in Apiqo Organics and Bizotic Lifescience via share swaps. The AOPL acquisition is valued at approximately ₹116.52 Crore.
Anlon Healthcare will hold a board meeting on August 11, 2026, to consider financial results, share capital changes, and preferential equity issuances for acquisitions.
Anlon Healthcare is transitioning to an integrated pharma player via strategic acquisitions. Reported FY26 revenue of ₹171.97 Cr with a 27.74% EBITDA margin, focusing on backward integration and high-value APIs.
Anlon Healthcare Limited reported Q1FY27 consolidated net profit growth of 133% to ₹8.28 Crore. Total income rose 163% to ₹87.62 Crore, driven by strategic acquisitions.
Anlon Healthcare Ltd reported revenue from operations of ₹87.6 Cr (+163.1% YoY) and net profit of ₹8.3 Cr (+137.1% YoY) for Q1 FY27.
Anlon Healthcare Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026. The filing discloses the company's current equity ownership distribution.
Anlon Healthcare scheduled a board meeting for July 30, 2026, to approve quarterly financial results and authorize the acquisition of shares in AOPL and BLPL.
Anlon Healthcare Ltd submitted its shareholding pattern for the quarter ended June 30, 2026, as per regulatory requirements.
Anlon Healthcare incorporated a 65% subsidiary, Anlon Biologics Private Limited, for Rs. 0.065 Crore. The unit will manufacture surgical implants and biosimilars.
Anlon Healthcare incorporated a 55% subsidiary, Anlon Medicare Private Limited, for Rs. 0.11 Crore. The new unit will manufacture surgical implants and medical devices.
Anlon Healthcare's board approved incorporation of two subsidiaries, investing up to Rs 1.75 million (₹0.175 Crore). The company will hold 55% and 65% equity respectively.
Anlon Healthcare Ltd reported revenue from operations of ₹33.3 Cr (-11.9% YoY) and net profit of ₹3.5 Cr (-7.9% YoY) for Q1 FY26.
Anlon Healthcare's Chairman and Managing Director participated in a media interview on Money TV. The discussion focused on FY 2025-26 performance and industry outlook.
Anlon Healthcare Limited reported FY26 consolidated total income of ₹172.22 Cr, up 42.98% YoY. Strategy focuses on API expansion and CDMO scaling.
Anlon Healthcare reports strong FY26 growth with revenues reaching ₹171.97cr, up from ₹120.29cr in FY25. Strategy focuses on backward integration and expansion via Bizotic and Apiqo acquisitions.
Anlon Healthcare reported FY26 consolidated revenue of ₹172.22 Crore, a 43% year-on-year increase. PAT grew 42% to ₹29.09 Crore, driven by strategic acquisitions and API demand.
Anlon Healthcare Ltd reported revenue from operations of ₹50.9 Cr (+4.1% YoY) and net profit of ₹11.1 Cr (-33.1% YoY) for Q4 FY26.
Anlon Healthcare approved audited FY26 financial results showing standalone total income of ₹176.75 Crore. The board also reviewed issue proceeds utilization and audit reports.